Re: Wikipedia on Investor Relations: Goal is Fair Valuation
in response to
by
posted on
May 27, 2016 02:18PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
SF, Don't get too alarmed.
The quote was : for Financial Reporting basis, the figure the company uses as of Jan 2016 was .38 cents US.
The Balance Sheet "Value" has no connection to a Market Value, or an actual value. Unfortunately, there is no Market for Zenith. In case of an insider buy-out, an independent appraisal would be required to establish an actual value.. So far, the number of shares sold did not trigger that requirement. Zenith could be worth a lot, or almost nothing.
I too would like to see an IPO, but only at a much higher value, if neccessary after some share consolidation (reverse split).
Deke
An aside: Ed Mirvish once said - "at my age I don't buy green bananas". I think I am not the only one here who should have applied that thinking to buying into RVX / Zenith.
For the younger set, look up Honest Ed, https://en.wikipedia.org/wiki/Honest_Ed%27s